Abstract
Currently, the diagnosis of patients with stroke and epilepsy is still a great challenge, since it is based on subjective clinical signs and symptoms. Therefore, the identification of biomarkers for the diagnosis and for the establishment of prognosis becomes essential. Methylated cell free circulating DNAs (cfDNAs) have recently emerged as candidates for biomarkers, since they can be eas…